Display options
Cite
Matulevicius V, Urbanavicius V, Lukosevicius S, et al. Importance of Dehydroepiandrosterone Sulfate Assessment with Special Attention for Adrenal Tumours and Arterial Hypertension. Acta Endocrinol (Buchar). 2021;17(1):68-76doi: 10.4183/aeb.2021.68.
Matulevicius, V., Urbanavicius, V., Lukosevicius, S., Banisauskaite, I., Donielaite, G., & Galkine, A. (2021). Importance of Dehydroepiandrosterone Sulfate Assessment with Special Attention for Adrenal Tumours and Arterial Hypertension. Acta endocrinologica (Bucharest, Romania : 2005), 17(1), 68-76. https://doi.org/10.4183/aeb.2021.68
Matulevicius, V, et al. "Importance of Dehydroepiandrosterone Sulfate Assessment with Special Attention for Adrenal Tumours and Arterial Hypertension." Acta endocrinologica (Bucharest, Romania : 2005) vol. 17,1 (2021): 68-76. doi: https://doi.org/10.4183/aeb.2021.68
Matulevicius V, Urbanavicius V, Lukosevicius S, Banisauskaite I, Donielaite G, Galkine A. Importance of Dehydroepiandrosterone Sulfate Assessment with Special Attention for Adrenal Tumours and Arterial Hypertension. Acta Endocrinol (Buchar). 2021 Apr-Jun;17(1):68-76. doi: 10.4183/aeb.2021.68. PMID: 34539912; PMCID: PMC8417495.
Copy Download .nbib Format: NLM
Share it on

Acta Endocrinol (Buchar). 2021 Apr-Jun;17(1):68-76. doi: 10.4183/aeb.2021.68.

Importance of Dehydroepiandrosterone Sulfate Assessment with Special Attention for Adrenal Tumours and Arterial Hypertension.

Acta endocrinologica (Bucharest, Romania : 2005)

V Matulevicius, V Urbanavicius, S Lukosevicius, I Banisauskaite, G Donielaite, A Galkine

Affiliations

  1. Lithuanian University of Health Sciences - Institute of Endocrinology, Department of Endocrinology.
  2. Lithuanian University of Health Sciences - Institute of Endocrinology, Vilnius University - Faculty of Medicine, Department of Endocrinology, Vilnius, Lithuania.
  3. Lithuanian University of Health Sciences - Institute of Endocrinology, Department of Radiology, Kaunas.

PMID: 34539912 PMCID: PMC8417495 DOI: 10.4183/aeb.2021.68

Abstract

OBJECTIVE: To investigate the significance of DHEAS assessment in males of different ages.

METHODS: Retrospective cohort study of patients investigated in two large academic centres.

RESULTS: The data of DHEAS assessment of 3533 patients (3013 females and 520 males) was analysed. DHEAS was 1.6 - 13.5 times more frequently investigated in women than in men. A peak of DHEAS evaluation test for women was at 25 years old and distribution was uniform in males over decades, excepting being lower in 0-9 and 75+ages. In the age group 10-24 years, DHEAS levels were higher in females. After 45 years, DHEAS was higher in men than in women. Analysis of 510 case records showed low DHEAS levels in boys (0-9 years) and in men aged 65 - 84+. Higher DHEAS levels were detected as a peak at 30 years old, but never after 55 years. In individuals with low DHEAS levels prevailed congenital adrenal hyperplasia (32%), adrenal tumours (30%) and primary or secondary adrenal insufficiency (19%). High DHEAS levels prevailed in patients with arterial hypertension (26%), overweight-obesity -(19%), non-toxic goiter (17%) and alopecia (9%). In the normal DHEAS miscellaneous diagnoses were met most frequently - 40%. Disorders exceeding 5% were non-toxic goiter (19%), adrenal tumours - 17%, overweight/obesity - 16% and arterial hypertension- 8%. In 71 women and 124 men adrenal neoplasms were detected. Higher frequency of these was observed in women in their 30s. A peak of adrenal neoplasms in men was at their 70s. This gender difference was not conditioned by earlier attempts to seek medical care by women. A significant correlation of DHEAS, weight, body mass index and systolic blood pressure with diastolic blood pressure was found.

CONCLUSION: Our study permits to determine which DHEAS secretion and clinical pattern might be associated in males of different ages.

©by Acta Endocrinologica Foundation.

Keywords: DHEAS; adrenal tumors; hypertension

References

  1. BMC Endocr Disord. 2016 Mar 17;16:15 - PubMed
  2. Mayo Clin Proc Innov Qual Outcomes. 2017 Dec 21;2(1):30-39 - PubMed
  3. J Endocrinol. 1997 Jul;154(1):57-62 - PubMed
  4. Best Pract Res Clin Endocrinol Metab. 2006 Jun;20(2):167-76 - PubMed
  5. J Bone Miner Res. 2017 Aug;32(8):1607-1614 - PubMed
  6. Endocr Rev. 2014 Apr;35(2):282-326 - PubMed
  7. Prog Brain Res. 2010;186:113-37 - PubMed
  8. Prog Neuropsychopharmacol Biol Psychiatry. 2017 Mar 6;74:31-35 - PubMed
  9. Am J Hypertens. 1998 May;11(5):532-8 - PubMed
  10. J Comorb. 2018 Oct 23;8(1):2235042X18806986 - PubMed
  11. Am J Epidemiol. 2001 Jan 1;153(1):79-89 - PubMed
  12. J Clin Endocrinol Metab. 2016 Feb;101(2):364-89 - PubMed
  13. J Sex Med. 2011 Nov;8(11):2960-82; quiz 2983 - PubMed
  14. J Clin Endocrinol Metab. 2010 Nov;95(11):4985-92 - PubMed
  15. J Hypertens. 2018 Nov;36(11):2237-2244 - PubMed
  16. Am J Respir Crit Care Med. 2016 May 15;193(10):1168-75 - PubMed
  17. J Am Geriatr Soc. 1990 Apr;38(4):421-7 - PubMed
  18. J Clin Endocrinol Metab. 1994 Dec;79(6):1532-9 - PubMed
  19. Urol Case Rep. 2020 Feb 26;31:101148 - PubMed
  20. Front Aging Neurosci. 2019 Mar 29;11:61 - PubMed
  21. Curr Opin Endocrinol Diabetes Obes. 2010 Jun;17(3):217-23 - PubMed
  22. J Clin Endocrinol Metab. 2018 Mar 1;103(3):1214-1223 - PubMed
  23. Ann Pediatr Endocrinol Metab. 2015 Mar;20(1):1-7 - PubMed
  24. Reprod Biol Endocrinol. 2013 May 16;11:44 - PubMed
  25. J Clin Endocrinol Metab. 1984 Sep;59(3):551-5 - PubMed
  26. Diabetologia. 2017 Jan;60(1):98-106 - PubMed
  27. Eur J Endocrinol. 2016 Aug;175(2):G1-G34 - PubMed
  28. J Clin Endocrinol Metab. 2010 Sep;95(9):4406-14 - PubMed
  29. Eur J Endocrinol. 2000 Jun;142(6):611-7 - PubMed
  30. Int J Endocr Oncol. 2016 May;3(2):161-174 - PubMed
  31. Eur J Endocrinol. 2019 Mar 1;180(3):213-221 - PubMed
  32. J Steroid Biochem Mol Biol. 2015 Jan;145:213-25 - PubMed
  33. J Gerontol A Biol Sci Med Sci. 2017 Jun 1;72(6):747-753 - PubMed
  34. Acta Endocrinol (Buchar). 2019 Jul-Sep;15(3):364-371 - PubMed
  35. J Clin Endocrinol Metab. 2008 Feb;93(2):400-9 - PubMed

Publication Types